Skip to main content
Equibles
AGEN logo

AGEN · Agenus Inc · Metrics

Track AGEN — free

Use AGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.93 +0.04 (+0.40%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 7, 2026
Market Cap
$427.47M
Shares
45.02M
Volume · Sep 30 1.37M Avg daily vol (3M) 4.21M

AGEN metrics

68 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.93
Market cap
$427.47M

Price action

20 metrics
Price change (1W)
+13.7%
Price change (30D)
+30.0%
Price change (3M)
+223.2%
Price change (6M)
+196.1%
Price change (YTD)
+215.0%
Price change (1Y)
+148.5%
Trailing year
Price change (5Y)
—
52-week high
$9.89
52-week low
$2.77
Change from 52-week high
+0.0%
Change from 52-week low
+257.0%
Annualized volatility
118.1%
Annualized volatility (3M)
188.2%
Beta
1.5
RSI (14D)
73.3
Price vs SMA 50
+31.4%
Price vs SMA 200
+118.7%
Avg volume (3M)
4.20M
Relative volume
0.4
Average dollar volume
$26.49M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
45.02M

Valuation

12 metrics
P / E (TTM)
3.3
Trailing earnings · reciprocal yield 30.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.0%
P / book
—
FCF yield
-23.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
21.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
87.3×
reciprocal yield 1.1%
EV / revenue historical average (3Y)
1.4×
reciprocal yield 72.6%
EV / revenue historical average (5Y)
2.6×
reciprocal yield 38.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
11.8×
reciprocal yield 8.5%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
8.7×
reciprocal yield 11.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
99.5%
Operating margin
27.3%
Trailing 12 months
Net margin
69.3%
Gross profit (TTM)
—
Operating profit (TTM)
$36.20M
Net income (TTM)
$91.94M
Trailing 12 months
Diluted EPS (TTM)
$3.04
FCF margin
-74.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-7.68

Growth

11 metrics
Revenue growth YoY
+34.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$132.69M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+47.0%
Year over year · more shares
Revenue CAGR (3Y)
+5.2%
Revenue CAGR (5Y)
+5.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
53.2%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
$40.93M
Free cash flow (TTM)
−$98.50M
Quick ratio
—
Interest coverage
0.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$18.74M
Total assets
$172.69M
Total debt
$60.14M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$98.50M
Capital expenditures (TTM)
$0
R&D (TTM)
$57.69M
SG&A (TTM)
—
Stock compensation (TTM)
$11.41M
R&D / revenue
43.5%
Stock compensation / revenue
8.6%

Ownership (13F)

3 metrics
13F filers
105
13F filer change QoQ
+17
Institutional ownership
31.9%

Short interest

3 metrics
Short interest
15.1%
Latest settlement · 7.7 days to cover
Days to cover
7.7d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1098972 CUSIP 00847G804 13F (30d) 2 filings 2 filers Visit website Investor relations